Dennis Joseph Slamon MD

Breast Cancer, Hematologic Oncology

UCLA School of Medicine

200 Medical 530 420 120 Plz# 365Los Angeles, CA 90095
Phone+1 310-825-5193
Fax+1 310-267-2301

Dr. Slamon is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Slamon's full profile Already have an account?

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1979 - 1981
University of ChicagoResidency, Internal Medicine, 1975 - 1979
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1975

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

IL State Medical License 1976 - Present
CA State Medical License 1979 - 2028
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2016
Elected Member The American Society for Clinical Investigation, 1988
Super Doctor SuperDoctors.com

Clinical Trials

Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. Start of enrollment: 2015 Jun 09
COMPLETED
PHASE3
Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In
COMPLETED
PHASE1, PHASE2
A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide Start of enrollment: 2017 Sep 05
COMPLETED
EARLY_PHASE1

Publications & Presentations

PubMed

Inhibition of Acetyl-CoA-carboxylase induces endoplasmic reticulum stress and augments the efficacy of anti-cancer therapies.
Naing Lin Shan, Henriette Balinda, Jiawei Dai, Yueyue Wang, Hao-Kuen Lin
Clinical Cancer Research. 2026-08-03
Expression of HER2 in the eye and the potential for on-target side effects with antibody-drug conjugates.
Simon Davenport, Bin Xie, Kevin Hamblett, Diana Hausman, Ivonne Villalobos
Scientific Reports. 2026-05-07
Pembrolizumab and epigenetic modification with azacitidine reshapes the tumor microenvironment of platinum-resistant epithelial ovarian cancer: a phase 2 non-randomize...
Blair V Landon, Julia L Boland, Andrea E Wahner Hendrickson, Deborah K Armstrong, Boris Winterhoff
Communications Medicine. 2026-02-06

Lectures

NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptorâ€“positive (HR+), human epidermal growth factor recept...
2019 ASCO Annual Meeting - 6/1/2019
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
University of California, Costa Mesa, California - 5/17/2013
Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2â€) advanced breast cancer (ABC): Results from MO...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

Plenary Panel Outlines Transformational Role of Patients and Survivors as Advocates, CollaboratorsDecember 12th, 2025
Cutting-Edge Advances in Combination Therapies for Liver and Pancreatic Cancers, Organoid Platforms for Personalized Head and Neck Cancer Treatment, and Breakthroughs in Liquid Biopsies for Early Cancer DetectionApril 17th, 2025
Including Biomarkers and Patient Preference in Treatment DecisionsMarch 24th, 2025

Grant Support

Cru - Clinical Research Unit Shared ResourceNational Cancer Institute2009–2012
The Transcription Factor SLUG May Drive The Progression Of AKT And Her2/NeuNational Cancer Institute2010–2011
Signal Transduction In OncogenesisNational Cancer Institute1995–2006
Academic Training In Medical OncologyNational Cancer Institute1991–2005
Core--Tissue BankNational Cancer Institute2002